東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pharmacokinetic and Pharmacodynamic ...

Sharma, Ankur.

FindBook

Google Book

Amazon

博客來

Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation./
作者:	Sharma, Ankur.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2017,
面頁冊數:	190 p.
附註:	Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.
Contained By:	Dissertation Abstracts International78-09B(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10257485
ISBN:	9781369714371

Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation.
Sharma, Ankur.

Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 190 p.

Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.

Thesis (Ph.D.)--The University of Oklahoma Health Sciences Center, 2017.

SHetA2 is a flexible heteroarotinoid (Flex-Het), which was selected as a lead from a series of Flex-Het based on potent induction of apoptosis in cancer cells. With the promising preclinical safety and efficacy profiles, SHetA2 is now moved forward for clinical development. Well-designed experiments in preclinical animal models and utilization of physiologically, mechanism-based pharmacokinetic and pharmacodynamic (PBPK/PD) models can provide better quantitation and prediction of the disposition and dynamics of SHetA2. The main goal of this thesis was to develop PBPK/PD models for SHetA2 that not only can provide improved understanding of SHetA2 PK/PD but also can assist more rationale design of Phase 0/I clinical trials of SHetA2, thereby decreasing risk of failure at the clinical development stage and making the clinical trial cost effective. (Abstract shortened by ProQuest.).

ISBN: 9781369714371Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation.
LDR:01901nmm a2200289 4500 001 2154189
005 20180330130621.5
008 190424s2017 ||||||||||||||||| ||eng d
020 $a 9781369714371
035 $a (MiAaPQ)AAI10257485
035 $a (MiAaPQ)ouhsc:10007
035 $a AAI10257485
040 $a MiAaPQ $c MiAaPQ
100 1 $a Sharma, Ankur. $3 2092078
245 1 0 $a Pharmacokinetic and Pharmacodynamic Characterization of Sheta2, A Novel Orally Bioavailable Anti-Cancer Drug Towards Clinical Translation.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 190 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.
500 $a Adviser: Sukyung Woo.
502 $a Thesis (Ph.D.)--The University of Oklahoma Health Sciences Center, 2017.
520 $a SHetA2 is a flexible heteroarotinoid (Flex-Het), which was selected as a lead from a series of Flex-Het based on potent induction of apoptosis in cancer cells. With the promising preclinical safety and efficacy profiles, SHetA2 is now moved forward for clinical development. Well-designed experiments in preclinical animal models and utilization of physiologically, mechanism-based pharmacokinetic and pharmacodynamic (PBPK/PD) models can provide better quantitation and prediction of the disposition and dynamics of SHetA2. The main goal of this thesis was to develop PBPK/PD models for SHetA2 that not only can provide improved understanding of SHetA2 PK/PD but also can assist more rationale design of Phase 0/I clinical trials of SHetA2, thereby decreasing risk of failure at the clinical development stage and making the clinical trial cost effective. (Abstract shortened by ProQuest.).
590 $a School code: 0361.
650 4 $a Pharmaceutical sciences. $3 3173021
690 $a 0572
710 2 $a The University of Oklahoma Health Sciences Center. $b Pharmaceutical Sciences. $3 3341912
773 0 $t Dissertation Abstracts International $g 78-09B(E).
790 $a 0361
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10257485